The German fibromyalgia consumer reports – a cross-sectional survey

BMC Musculoskeletal Disorders

Andreas Winkelmann^1,10  Frederick Wolfe⁴  Thomas Weiss¹  Reinhard Thoma⁷  Jost Langhorst³  Franz Petermann⁵  Hedi Kühn-Becker²  Mechthild Gesmann⁸  Brigitte Erbslöh-Möller⁶  Eva Jung⁹  Winfried Häuser⁹ 

[1] Day clinic Mannheim Dr. Weiss, Mannheim, D-68161, Germany;Psychosomatic medicine and pain therapy office, Zweibrücken, D-66432, Germany;Department Internal Medicine V (Integrative Medicine), Kliniken Essen-Mitte, Universität Essen-Duisburg, Essen, D-45726, Germany;National Data Bank for Rheumatic Diseases, Wichita, Kansas and University of Kansas School of Medicine, Wichita, KS, USA;Centre of clinical psychology and rehabilitation, Universität Bremen, Bremen, D- 28359, Germany;Rheumatology Office, Neunkirchen, D-66538, Germany;Algesiologikum München, München, 80799, Germany;Psychosomatic medicine and pain therapy office, Herford, D- 32049, Germany;Department of Psychosomatic medicine and psychotherapy, Technische Universität München, München, D-81675, Germany;Department of Physical Medicine and Rehabilitation, Klinikum der, Universität München, München, D-80336, Germany

关键词: Non-pharmacological therapies;    Drugs;    Consumer reports;    Fibromyalgia syndrome;   

Others  :  1149861
DOI  :  10.1186/1471-2474-13-74

 received in 2011-11-28, accepted in 2012-05-07,  发布年份 2012

【 摘 要 】

Background

Consumer surveys provide information on effectiveness and side effects of medical interventions in routine clinical care. A report of fibromyalgia syndrome (FMS) consumers has not been carried out in Europe.

Methods

The study was carried out from November 2010 to April 2011. Participants diagnosed with FMS rated the effectiveness and side effects of pharmacological and non-pharmacological FMS interventions on a 0 to 10 scale, with 10 being most efficacious (harmful). The questionnaire was distributed by the German League for people with Arthritis and Rheumatism and the German Fibromyalgia Association to their members and to all consecutive FMS patients of nine clinical centers of different levels of care.

Results

1661 questionnaires (95% women, mean age 54 years, mean duration since FMS diagnosis 6.8 years) were analysed. The most frequently used therapies were self-management strategies, prescription pain medication and aerobic exercise. The highest average effectiveness was attributed to whole body and local warmth therapies, thermal bathes, FMS education and resting. The highest average side effects were attributed to strong opioids, local cold therapy, gamma-amino-butyric acid analogues (pregabalin and gabapentin), tramadol and opioid transdermal systems.

Conclusion

The German fibromyalgia consumer reports highlight the importance of non-pharmcological therapies in the long-term management of FMS, and challenges the strong recommendations for drug therapies given by FMS-guidelines.

【 授权许可】

   
2012 Hauser et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, Russell AS, Russell IJ, Winfield JB, Yunus MB: The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken) 2010, 62(5):600-10.
• [2]Häuser W, Zimmer C, Felde E, Köllner V: What are the key symptoms of fibromyalgia? Results of a survey of the German Fibromyalgia Association. Schmerz 2008, 22(2):176-83. German
• [3]Choy E, Perrot S, Leon T, Kaplan J, Petersel D, Ginovker A, Kramer E: A patient survey of the impact of fibromyalgia and the journey to diagnosis. BMC Health Serv Res 2010, 10:102. BioMed Central Full Text
• [4]Winkelmann A, Perrot S, Schaefer C, Ryan K, Chandran A, Sadosky A, Zlateva G: Impact of fibromyalgia severity on health economic costs: results from a European cross-sectional study. Appl Health Econ Health Policy 2011, 9(2):125-36.
• [5]Branco JC, Bannwarth B, Failde I, Abello Carbonell J, Blotman F, Spaeth M, Saraiva F, Nacci F, Thomas E, Caubère JP, Le Lay K, Taieb C, Matucci-Cerinic M: Prevalence of fibromyalgia: a survey in five European countries. Semin Arthritis Rheum 2010, 39(6):448-53.
• [6]Häuser W, Schmutzer G, Glaesmer H, Brähler E: Prevalence and predictors of pain in several body regions. Results of a representative German population survey. Schmerz 2009, 23(5):461-70. German
• [7]Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Häuser W, Katz RS, Mease P, Russell AS, Russell IJ, Winfield JB: Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. J Rheumatol 2011, 38(6):1113-22.
• [8]Bradley LA: Pathophysiology of fibromyalgia. Am J Med 2009, 122(12 Suppl):S22-30.
• [9]Lempp HK, Hatch SL, Carville SF, Choy EH: Patients' experiences of living with and receiving treatment for fibromyalgia syndrome: a qualitative study. BMC Musculoskelet Disord 2009, 10:124. BioMed Central Full Text
• [10]Burckhardt CS, Goldenberg D, Crofford L, Gerwin R, Gowans S, Kackson K, et al.: Guideline for the management of fibromyalgia syndrome. Pain in adults and children. APS Clinical Practice Guideline Series No. 4. American Pain Society, Glenview, IL; 2005.
• [11]Carville SF, Arendt-Nielsen S, Bliddal H, Blotman F, Branco JC, Buskila D, Da Silva JA, Danneskiold-Samsøe B, Dincer F, Henriksson C, Henriksson KG, Kosek E, Longley K, McCarthy GM, Perrot S, Puszczewicz M, Sarzi-Puttini P, Silman A, Späth M, Choy EH: EULAR. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 2008, 67(4):536-41.
• [12]Häuser W, Eich W, Herrmann M, Nutzinger DO, Schiltenwolf M, Henningsen P: Fibromyalgia syndrome: classification, diagnosis, and treatment. Dtsch Arztebl Int 2009, 106(23):383-91.
• [13]Seligman M: The effectiveness of psychotherapy. The consumers Reports Study. Am Psychol 1990, 50:965-74.
• [14]Bennett RM, Jones J, Turk DC, Russell IJ, Matallana L: An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord 2007, 9(8):27.
• [15]Goldenberg DL: Diagnosis and differential diagnosis of fibromyalgia. Am J Med 2009, 122(12 Suppl):S14-21.
• [16]Häuser W, Hayo S, Biewer W, Gesmann M, Kühn-Becker H, Petzke F, von Wilmoswky H, Langhorst J: Diagnosis of fibromyalgia syndrome-a comparison of Association of the Medical Scientific Societies in Germany, survey, and American College of Rheumatology criteria. Clin J Pain 2010, 26(6):505-11.
• [17]Kroenke K, Spitzer RL, Jannett BW, Williams DSW, Löwe B: An Ultra-Brief Screening Scale for Anxiety and Depression: The PHQ–4. Psychosomatics 2009, 50:613-621.
• [18]Löwe B, Wahl I, Rose M, Spitzer C, Glaesmer H, Wingenfeld K, Schneider A, Brähler E: A 4-item measure of depression and anxiety: validation and standardization of the Patient Health Questionnaire-4 (PHQ-4) in the general population. J Affect Disord 2010, 122(1–2):86-95.
• [19]PatientsLikeme http://www.patientslikeme.com/conditions/8 webcite. Accessed november 20, 2011
• [20]Fuchs-Strizek R, Laireiter AR, Baumann U, Hessler E: Retrospective follow-up design in studying psychotherapeutic effectiveness-criteria and application. Psychother Psychosom Med Psychol 2011, 61(6):262-268. German